KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ClearPoint Neuro (CLPT) Research & Development (2018 - 2025)

ClearPoint Neuro's Research & Development history spans 13 years, with the latest figure at $3.5 million for Q3 2025.

  • For Q3 2025, Research & Development rose 4.13% year-over-year to $3.5 million; the TTM value through Sep 2025 reached $14.0 million, up 19.47%, while the annual FY2024 figure was $12.4 million, 5.83% up from the prior year.
  • Research & Development for Q3 2025 was $3.5 million at ClearPoint Neuro, down from $3.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $3.8 million in Q2 2025 and bottomed at $1.6 million in Q1 2021.
  • The 5-year median for Research & Development is $2.9 million (2022), against an average of $2.9 million.
  • The largest annual shift saw Research & Development skyrocketed 159.73% in 2021 before it fell 13.45% in 2024.
  • A 5-year view of Research & Development shows it stood at $3.0 million in 2021, then decreased by 2.69% to $2.9 million in 2022, then decreased by 9.4% to $2.7 million in 2023, then grew by 25.64% to $3.3 million in 2024, then increased by 3.6% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for CLPT's Research & Development are $3.5 million (Q3 2025), $3.8 million (Q2 2025), and $3.4 million (Q1 2025).